World Drug Safety Congress Europe 2025: Key Insights

The 2025 World Drug Safety Congress Europe, held on October 7 and 8, 2025, in Amsterdam, Netherlands, focused on the transformation of drug safety driven by technological innovation, evolving regulatory requirements, and an increased emphasis on patient perspectives.

The event convened between 1,500 and 1,800 global leaders and experts at the Amsterdam RAI to address critical challenges in pharmacovigilance and the implementation of next-generation safety solutions.

Integration of AI and Big Data in Pharmacovigilance

A central theme of the congress was the application of innovative technologies to improve patient safety. Experts explored the use of big data and artificial intelligence (AI) to modernize pharmacovigilance practices.

The discussions highlighted how safety solutions leveraging AI and cloud technologies serve as disruptive tools. These technologies are intended to help create a culture and community of innovation while simultaneously enhancing the monitoring of drug safety.

Patient-Centric Approaches and Risk Management

The congress emphasized a shift toward incorporating patient perspectives into the landscape of drug safety. This included examining patient-centric approaches to ensure that the experiences of patients are integrated into safety evaluations.

In addition to patient perspectives, the event focused on the examination of benefit-risk management strategies. These strategies are critical for evaluating the safety profile of medications and determining the balance between therapeutic benefits and potential risks.

Collaboration Between Regulators and Industry

The meeting was designed to bridge the gap between international regulatory bodies, industry professionals, and patient representatives. By bringing together key actors across various geographical regions and industries, the congress sought to align safety standards.

The event was organized by Terrapinn Ltd and aimed to facilitate a collaborative environment where regulatory requirements and industry innovations could be synchronized to improve overall public health outcomes.